Table 1

36 human cancer cell lines tested in 3-day MTT assays

Colon	Stomach	Breast
DLD-1 (1250/well, 16.8 h)	GT3TKB (2000/well, 21.1 h)	BSY-1 (2000/well, 46.1 h)
HCT15 (1500/well, 14.5 h)	HGC27 (1500/well, 14.6 h)	HBC5 (2000/well, 31.8 h)
HCT116 (1250/well, 13.4 h)	MKN1 (4000/well, 35.9 h)	MCF-7 (3000/well, 29.5 h)
HT29 (2500/well, 19.8 h)	MKN7 (3000/well, 37.4 h)	MDA-MB231 (2000/well, 21.6 h)
SW480 (3000/well, 19.5 h)	MKN28 (2000/well, 22.7 h)	MDA-MB-435 (3000/well, 24.4 h)
SW620 (2500/well, 17.3 h)	MKN74 (4000/well, 24.8 h)	MDA-MB-468 (3000/well, 34.2 h)
WiDr (2000/well, 18.9 h)		
Lung	**Pancreas**	**Leukemia**
A427 (2500/well, 32.4 h)	AsPC-1 (2500/well, 28.4 h)	CCRF-CEM (1500/well, 27.2 h)
A549 (1250/well, 18.9 h)	KP-1 (2000/well, 24.8 h)	HL60 (1500/well, 29.5 h)
LX-1 (2000/well, 17.2 h)	KP-4 (2000/well, 16.7 h)	K562 (1500/well, 20.6 h)
NCI-H460 (1000/well, 13.6 h)	MiaPaCaII (2500/well, 19.1 h)	MOLT-4 (1500/well, 22.3 h)
NCI-H522 (4000/well, 80.4 h)	PANC-1 (2500/well, 27.9 h)	
PC-9 (2000/well, 23.7 h)	SUIT-2 (2000/well, 15.6 h)	
PC-10 (2000/well, 24.0 h)		
Cell line (initial cell number, doubling time)		

[0235] Table 1 shows the type, initial cell number and doubling time of human cancer cell lines in human cancer cell line panels.

[0236] Cells of these cell lines were seeded in 96-well microplates (flat-bottomed) (50 μl/well) at the cell numbers indicated in Table 1. After 24 hours, a 3-fold dilution series of each compound was added (50 μl/well). After 72 hours, WST-8 (10 μl/well) was further added and the absorbance at 450 nm was measured. The least squares method was used to determine the 50% growth inhibitory concentration of each compound against all 36 cancer cell lines, followed by comparing the pattern of growth inhibition between compounds. As indexes of correlation, Pearson's correlation coefficients were used (Paull, K. D. et al. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J. Natl. Cancer Inst. 1989, 81, 1088-1092; Monks, A. et al. Feasibility of a high-flux anti-cancer drug screen using a diverse panel of cultured human tumor cell lines. J. Natl. Cancer Inst. 1991, 83, 757-766).